文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

维生素C、硫胺素和氢化可的松对脓毒症患者无呼吸机和无血管升压药天数的影响:VICTAS随机临床试验

Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在脓毒症危重患者中,维生素C、硫胺素和氢化可的松每6小时一次与安慰剂相比未显著增加30天内无呼吸机和无血管升压药天数。

VICTAS是一项在美国43家医院急诊科或ICU开展的多中心、随机、双盲、适应性样本量、安慰剂对照试验,纳入脓毒症所致呼吸和/或心血管功能障碍的成年患者501例。干预组接受静脉维生素C 1.5 g、硫胺素100 mg和氢化可的松50 mg每6小时一次,共96小时或至ICU出院或死亡;对照组接受匹配安慰剂。主要终点30天内无呼吸机和无血管升压药天数组中位数干预组25天(IQR 0-29)vs 安慰剂组26天(IQR 0-28),中位差异-1天(95%CI -4至2天;P=0.85),未达统计学显著。30天死亡率干预组22% vs 安慰剂组24%。试验因行政原因提前终止,可能把握度不足。

要点

  • 脓毒症危重患者中,维生素C 1.5 g+硫胺素100 mg+氢化可的松50 mg每6小时一次与安慰剂相比,30天内无呼吸机和无血管升压药天数组中位数25天 vs 26天,中位差异-1天(95%CI -4至2天;P=0.85)。
  • 30天死亡率干预组22% vs 安慰剂组24%。
  • 开放标签糖皮质激素在干预组33%、对照组32%的患者中使用,研究药物在开放标签氢化可的松等效日剂量≥200 mg时暂停。
  • 试验纳入501例后因资金撤回行政终止,可能把握度不足,未能检测临床重要差异。
  • 研究人群为脓毒症所致呼吸和/或心血管功能障碍的成年患者,中位APACHE II评分27,中位SOFA评分9。

适用人群与场景

  • 美国43家医院急诊科或ICU收治的成年脓毒症患者,伴呼吸和/或心血管功能障碍。
  • 纳入时间2018年8月至2019年7月,随机化501例,中位年龄62岁(IQR 50-70),46%女性,30%黑人。

处置流程与药物剂量

  • 干预组:静脉维生素C 1.5 g、硫胺素100 mg和氢化可的松50 mg每6小时一次,共96小时或至ICU出院或死亡。
  • 对照组:匹配安慰剂。
  • 临床团队可给予开放标签糖皮质激素;若开放标签氢化可的松等效日剂量≥200 mg,则暂停研究氢化可的松或匹配安慰剂。

研究设计与关键结果

  • 多中心、随机、双盲、适应性样本量、安慰剂对照试验,43家美国医院,501例脓毒症所致呼吸和/或心血管功能障碍成年患者,干预组252例 vs 安慰剂组249例。
  • 主要终点30天内无呼吸机和无血管升压药天数组:干预组中位数25天(IQR 0-29)vs 安慰剂组26天(IQR 0-28),中位差异-1天(95%CI -4至2天;P=0.85),未达统计学显著。
  • 关键次要终点30天死亡率:干预组22% vs 安慰剂组24%。
  • 开放标签糖皮质激素使用:干预组33% vs 对照组32%。
  • 试验在纳入501例后因资金撤回行政终止,所有随访于2020年1月完成。

证据类型、等级与局限

  • 证据类型:多中心、随机、双盲、适应性样本量、安慰剂对照试验(RCT)。
  • 局限:试验因行政原因提前终止,可能把握度不足,未能检测临床重要差异。

对床旁实践的改变

  • 对于脓毒症所致呼吸和/或心血管功能障碍的成年患者,维生素C、硫胺素和氢化可的松每6小时一次与安慰剂相比未显著增加30天内无呼吸机和无血管升压药天数,未显著降低30天死亡率(22% vs 24%)。
  • 试验因行政原因提前终止,可能把握度不足,作者结论未给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sepsis is a common syndrome with substantial morbidity and mortality. A combination of vitamin C, thiamine, and corticosteroids has been proposed as a potential treatment for patients with sepsis.

OBJECTIVE: To determine whether a combination of vitamin C, thiamine, and hydrocortisone every 6 hours increases ventilator- and vasopressor-free days compared with placebo in patients with sepsis.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, adaptive-sample-size, placebo-controlled trial conducted in adult patients with sepsis-induced respiratory and/or cardiovascular dysfunction. Participants were enrolled in the emergency departments or intensive care units at 43 hospitals in the United States between August 2018 and July 2019. After enrollment of 501 participants, funding was withheld, leading to an administrative termination of the trial. All study-related follow-up was completed by January 2020.

INTERVENTIONS: Participants were randomized to receive intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours (n = 252) or matching placebo (n = 249) for 96 hours or until discharge from the intensive care unit or death. Participants could be treated with open-label corticosteroids by the clinical team, with study hydrocortisone or matching placebo withheld if the total daily dose was greater or equal to the equivalent of 200 mg of hydrocortisone.

MAIN OUTCOMES AND MEASURES: The primary outcome was the number of consecutive ventilator- and vasopressor-free days in the first 30 days following the day of randomization. The key secondary outcome was 30-day mortality.

RESULTS: Among 501 participants randomized (median age, 62 [interquartile range {IQR}, 50-70] years; 46% female; 30% Black; median Acute Physiology and Chronic Health Evaluation II score, 27 [IQR, 20.8-33.0]; median Sequential Organ Failure Assessment score, 9 [IQR, 7-12]), all completed the trial. Open-label corticosteroids were prescribed to 33% and 32% of the intervention and control groups, respectively. Ventilator- and vasopressor-free days were a median of 25 days (IQR, 0-29 days) in the intervention group and 26 days (IQR, 0-28 days) in the placebo group, with a median difference of -1 day (95% CI, -4 to 2 days; P = .85). Thirty-day mortality was 22% in the intervention group and 24% in the placebo group.

CONCLUSIONS AND RELEVANCE: Among critically ill patients with sepsis, treatment with vitamin C, thiamine, and hydrocortisone, compared with placebo, did not significantly increase ventilator- and vasopressor-free days within 30 days. However, the trial was terminated early for administrative reasons and may have been underpowered to detect a clinically important difference.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03509350.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Sevransky JE, Rothman RE, Hager DN, et al. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial. JAMA. 2021. PMID: 33620405. doi:10.1001/jama.2020.24505

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。